论文部分内容阅读
卵巢肉瘤是非常罕见的妇女生殖道恶性肿瘤,多数发生在单侧卵巢,体积较大,实性多见。术前诊断率低,超声检查,CT和核磁共振对卵巢肉瘤的诊断有一定的参考价值,确切的诊断依赖术后病理。卵巢肉瘤目前尚无可靠的肿瘤标记物,除了血清CA125可升高外,术后标本的免疫组化检测也可呈现某些蛋白的阳性染色。目前采用卵巢癌的FIGO分期系统。治疗以手术为主,术后联合放疗或化疗。化疗方案的选择及患者对化疗的反应,与肿瘤的病理类型及临床分期密切相关。手术分期是影响其预后的重要因素。
Ovarian sarcoma is a very rare female reproductive tract cancer, most occur in unilateral ovarian, larger, more solid reality. Preoperative diagnosis is low, ultrasound, CT and MRI of ovarian sarcoma diagnosis has a certain reference value, the exact diagnosis depends on postoperative pathology. Ovarian sarcoma is currently no reliable tumor markers, in addition to serum CA125 can be increased, the immunohistochemical detection of postoperative specimens may also present some protein positive staining. Currently using the FIGO staging system for ovarian cancer. The main treatment of surgery, postoperative radiotherapy or chemotherapy. The choice of chemotherapy regimen and the patient’s response to chemotherapy are closely related to the pathological type and clinical stage of the tumor. Staging is an important factor affecting the prognosis.